Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
+1 more
25x-NBOHLSD, psilocybin, mescaline +4 moreLSD, psilocybin, mescaline, 25I-NBOMe, 25CN-NBOH, other NBOH compounds, other serotonergic psychedelics show less
25I-NBOH
4-iodo-2,5-dimethoxy-N-(2-hydroxybenzyl)phenethylamine
25I-NBOH is a synthetic psychedelic of the phenethylamine class. It is a close structural relative of 25I-NBOMe, sharing its high potency but differing in how the body metabolizes it. It activates serotonin receptors in the brain, producing the visual and cognitive shifts characteristic of classical psychedelics.
25I-NBOH (2-[[2-(4-iodo-2,5-dimethoxyphenyl)ethylamino]methyl]phenol) is a synthetic psychedelic of the phenethylamine class. It is the ortho-hydroxybenzyl structural analog of 25I-NBOMe, sharing its high potency but differing in metabolism and thermal stability. 25I-NBOH is a full agonist at the 5-HT₂A receptor, producing its effects through Gq-protein-coupled signaling that disrupts normal cortical processing.[1]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
+1 more
25x-NBOHLSD, psilocybin, mescaline +4 moreLSD, psilocybin, mescaline, 25I-NBOMe, 25CN-NBOH, other NBOH compounds, other serotonergic psychedelics show less
Its structural scaffold was characterized in 2006, when adding an N-benzyl group to 2C-class compounds was shown to increase serotonin binding 300-fold.[1] 25I-NBOH appeared on research chemical markets around 2010 and was first forensically confirmed in seized blotter papers from Brazil in 2017.[2] It remains unscheduled under international conventions, circulating on unregulated markets where product identity is unreliable.
Subjective effects include geometric visual patterns, color enhancement, thought acceleration, emotional enhancement, and sustained physical stimulation. The experience is defined by its body weight — vasoconstriction, elevated heart rate, and temperature instability form a persistent physical backdrop absent from psilocybin or DMT. Nausea, muscle tension, anxiety, and perceptual disturbances lasting days after use are common.
25I-NBOH produces no physical dependence, but no lethal dose or safety margin has been established for any species. The main danger is a narrow, uncharacterized gap between common and dangerous doses, compounded by unreliable product identity on unregulated markets.[3] No controlled human studies exist — current understanding comes from preclinical data, community reports, and structural analog inference from 25I-NBOMe fatalities.[4]
History[edit]
Discovery
The structural scaffold for 25I-NBOH was established in 2006, when researchers demonstrated that attaching an N-benzyl group to 2C-class phenethylamines could increase serotonin receptor binding by up to 300-fold.[1] The NBOMe series reached research chemical markets around 2010–2011; the NBOH series followed shortly after. The precise date of 25I-NBOH's first synthesis has not been published.
Forensic identification and market presence
25I-NBOH was first confirmed in seized blotter papers from Brazil in 2017, with individual dose loads ranging from 300 to 1,000 µg.[2] A key complication: the compound breaks down under standard forensic heat testing, causing it to be misidentified as 2C-I.[2][5][6] It was likely present in earlier seizures but recorded under the wrong name.
Scheduling and scientific characterization
Regulatory action has proceeded jurisdiction by jurisdiction, generally trailing behind the more documented 25I-NBOMe. Louisiana scheduled 25I-NBOH in June 2013,[7] Sweden in August 2015,[7] and Brazil around the same period.[2] Product reliability remains poor — one analyzed sample sold as "25I-NBOH" contained entirely different substances, including a stimulant.[3]
The "NBOH" designation comes from the compound's defining structural feature: an N-(2-hydroxybenzyl) group attached to the phenethylamine nitrogen. The "25I" prefix follows Alexander Shulgin's numbering convention — "25" marks the N-benzyl derivative, and "I" indicates the iodine atom at the 4-position. The compound is sometimes confused with or sold as 25I-NBOMe despite meaningful differences in metabolism, stability, and potentially safety profile.
Chemistry[edit]
Structural class
25I-NBOH belongs to the substituted phenethylamine family, specifically the 25x-NBOH series. Its parent compound is 2C-I, first documented by Alexander Shulgin.citation needed Adding a 2-hydroxybenzyl group to the amine nitrogen increases serotonin receptor binding affinity by up to 300-fold[1] — a single structural change that converts a moderately potent compound into an extremely potent one.
Molecular properties
| Molecular formula | C₁₇H₂₀INO₃ |
| Molecular weight | 413.25 g/mol |
The 2,5-dimethoxy substitution pattern is essential for psychedelic activity — removing either methoxy group markedly reduces potency beyond what binding data alone would predict.[8] The NBOH scaffold differs from the closely related NBOMe series by one functional group: a free hydroxyl instead of a methoxy, changing how the body metabolizes it and how it behaves under heat.[9]
Pharmacology[edit]
Mechanism of action
25I-NBOH is a potent full agonist at serotonin receptors, with functional potency comparable to LSD.[10] It does not affect dopamine or norepinephrine reuptake — stimulant-like effects come entirely from serotonin activity.[10] Research shows that serotonin's Gq signaling pathway is what correlates with psychedelic potential.[11]
Pharmacokinetics
No human pharmacokinetic data have been published — bioavailability, peak timing, and half-life are unknown. The body processes 25I-NBOH primarily through the liver enzyme CYP2D6 — a different enzyme than the one used to clear 25I-NBOMe.[9] People with non-functional CYP2D6 genes, and those taking antidepressants that block this enzyme, may experience substantially stronger and longer-lasting effects.[9]
Neuroscience[edit]
Where it acts
No human brain imaging data exist for 25I-NBOH. As a potent serotonin receptor agonist, it is expected to activate specific neurons in the prefrontal cortex — the primary cellular trigger for serotonergic psychedelic effects. Studies using a related compound show this creates a push-pull dynamic: sensory input is heightened while overall firing is suppressed, which may explain why heightened perception coexists with impaired executive function.[12]
Theoretical frameworks
The leading framework holds that potent serotonin activation disrupts the brain's normal processing hierarchy, weakening its reliance on prior expectations and increasing neural flexibility.citation needed This produces the visual shifts, heightened sense of meaning, and boundary dissolution characteristic of psychedelics. Animal recordings during 25I-NBOH use show a distinctive slow brainwave pattern accompanying behavioral changes.[13]
- Does 25I-NBOH promote structural neuroplasticity (new synaptic connections) in cortical neurons, and does this require sustained exposure or a single dose?
- The related compound 25I-NBOMe blocks memory-related brain processes through a mechanism not reversed by blocking serotonin receptors[14] — does 25I-NBOH share this potentially neurotoxic property?
- Can the distinctive slow brainwave pattern observed in mice[13] be detected in human EEG, and does it correspond to identifiable subjective states?
Subjective Effects[edit]
25I-NBOH is a serotonergic psychedelic defined by its physical weight. Geometric visuals and altered thinking unfold over a persistent backdrop of cardiovascular arousal, vasoconstriction, and temperature changes. The body is rarely quiet. Anxiety about the compound's uncertain safety profile can color the entire experience.
Within the N-benzylphenethylamine family, it sits closest to 25I-NBOMe — similar potency, similar body load, shorter duration than LSD. The physical activation is substantially more intense than psilocybin or DMT. The narrow and uncharacterized gap between a common dose and a dangerous one creates a different risk-awareness context throughout the experience.
The N-benzyl phenethylamine scaffold was characterized in 2006 at Purdue University, when adding an N-arylmethyl group to 2C-class compounds was shown to dramatically increase 5-HT₂A binding affinity.[2] 25I-NBOH appeared on research chemical markets between 2010 and 2015 and was first forensically identified in seized blotter papers from Brazil in 2017.[3] It remains unscheduled under United Nations conventions and circulates in small quantities on unregulated markets, where product integrity is unreliable.
Subjective effects include geometric visual patterns, color enhancement, thought acceleration, emotional enhancement, and sympathomimetic stimulation. The experience is marked by pronounced physical intensity — vasoconstriction, temperature dysregulation, and cardiovascular arousal form a persistent somatic backdrop that distinguishes it from classical tryptamine psychedelics. Nausea, muscle tension, anxiety, and lingering perceptual disturbances lasting days after use are common unsought effects.
25I-NBOH produces no physical dependence, but no lethal dose, therapeutic index, or human pharmacokinetic parameters have been established. The primary danger is a narrow and uncharacterized margin between common and potentially dangerous doses — compounded by unreliable product identity on unregulated markets.[4] No controlled human studies exist; the current understanding rests entirely on preclinical pharmacology, analog inference from 25I-NBOMe fatalities,[5] and community reports.
History[edit]
Discovery
The structural foundation for 25I-NBOH was laid in 2006, when researchers at Purdue University demonstrated that attaching an N-arylmethyl group to 2C-class phenethylamines increases 5-HT₂A binding affinity by up to 300-fold.[2] The NBOMe series (N-2-methoxybenzyl) entered research chemical markets around 2010–2011 as potent psychedelic agents; the NBOH series (N-2-hydroxybenzyl), distinguished by a free phenol group in place of the methoxy, followed shortly after. The precise date of 25I-NBOH's first synthesis is not documented in the peer-reviewed literature.
Forensic identification and market presence
25I-NBOH was first scientifically identified in seized blotter papers from Brazil in 2017, with individual dose loads ranging from 300 to 1,000 µg.[3] A critical analytical complication emerged: the compound degrades to its parent phenethylamine 2C-I under standard gas chromatography conditions,[3][6][7] meaning it was likely present in earlier seizures but systematically misidentified. Market reliability remains poor — one documented case found powder labeled as "25I-NBOH" actually contained 25E-NBOH combined with a synthetic cathinone stimulant, with no 25I-NBOH present.[4]
Scheduling and scientific characterization
Regulatory action has proceeded on a jurisdiction-by-jurisdiction basis, generally lagging behind the more documented 25I-NBOMe. Louisiana scheduled 25I-NBOH in June 2013,[8] Sweden followed in August 2015,[8] and Brazil added it to its controlled substances list around the same period.[3] The publication of formal pharmacological data in 2017–2018[9][10] transitioned the compound from an analytically identified market substance to a scientifically profiled tool compound.
The "NBOH" designation derives from the compound's defining structural feature: an N-(2-hydroxybenzyl) group attached to the phenethylamine nitrogen. The "25I" prefix follows the convention established by Alexander Shulgin's numbering of 2C-series phenethylamines — "25" denotes the N-benzyl derivative, and "I" indicates the iodine substituent at the 4-position. The compound is sometimes confused with or sold as 25I-NBOMe, its methoxybenzyl counterpart, despite meaningful differences in metabolism, stability, and potentially in safety profile.
Chemistry[edit]
Structural class
25I-NBOH belongs to the substituted phenethylamine family, specifically the 25x-NBOH series. Its parent compound is 2C-I (2,5-dimethoxy-4-iodophenethylamine), a psychedelic phenethylamine first documented by Alexander Shulgin.citation needed The defining modification is the addition of a 2-hydroxybenzyl group to the amine nitrogen — a change that increases 5-HT₂A receptor binding affinity by up to 300-fold.[2]
The NBOH scaffold differs from the closely related NBOMe series by a single functional group: NBOH carries a free hydroxyl (phenol), while NBOMe carries a methoxy group (anisole). This distinction affects thermal stability, analytical detection, and how the body metabolizes each compound.[10]
Molecular properties
| Molecular formula | C₁₇H₂₀INO₃ |
| Molecular weight | 413.25 g/mol |
The molecule comprises a 2,5-dimethoxyphenethylamine core bearing an iodine atom at the 4-position and an N-(2-hydroxybenzyl) group. The iodine accounts for roughly 31% of the total molecular weight and influences how the compound fits within the 5-HT₂A binding pocket. The 2,5-dimethoxy substitution pattern is essential for full psychedelic activity: removal of either methoxy group markedly reduces potency in animal models beyond what binding data alone would predict.[11]
Stereochemistry
25I-NBOH possesses no chirality centers and exists as a single achiral species. No stereochemical considerations apply to its activity.
Physical properties and analytical detection
No published data exist for the melting point, solubility, or long-term stability of 25I-NBOH. The compound is typically distributed as a hydrochloride salt.citation needed
The defining physical characteristic is thermal instability. 25I-NBOH breaks down to its parent compound 2C-I under standard gas chromatography conditions, causing systematic misidentification in forensic laboratories.[3][6][7] Reliable identification requires liquid chromatography methods or chemical derivatization prior to gas chromatography.[7][6]
Pharmacology[edit]
Mechanism of action
25I-NBOH is a potent full agonist at serotonin 5-HT₂A and 5-HT₂C receptors, with functional potency comparable to LSD.[9] It has negligible activity at monoamine transporters, meaning it does not produce stimulant effects through dopamine or norepinephrine reuptake.[9]
Psychedelic effects are driven by Gq-protein signaling at the 5-HT₂A receptor. Research across a large panel of 5-HT₂A agonists has shown that this Gq pathway — not the alternative β-arrestin2 pathway — is what correlates with psychedelic potential.[1] The 2,5-dimethoxy groups on the phenethylamine core are structurally essential: removing either one reduces psychedelic activity in animals far more than binding data alone would predict.[11]
Pharmacokinetics
No human pharmacokinetic data (bioavailability, time to peak, plasma half-life) have been published. All metabolic data come from laboratory microsomal studies.
25I-NBOH is primarily metabolized by the liver enzyme CYP2D6 — a notable difference from 25I-NBOMe, which relies on CYP3A4.[10] The compound is cleared roughly 1.7 times faster than 25I-NBOMe in microsomal assays.[10]
This CYP2D6 dependence has practical consequences. Strong CYP2D6 inhibitors — including fluoxetine, paroxetine, and bupropion — may substantially increase 25I-NBOH exposure. Individuals who are genetically CYP2D6 poor metabolizers may experience elevated and prolonged effects.[10] A secondary glucuronidation pathway may partially offset this variability.
Neuroscience[edit]
Where it acts
No human neuroimaging data exist for 25I-NBOH. As a potent 5-HT₂A full agonist, it is expected to activate layer V pyramidal neurons in the prefrontal cortex — the primary cellular trigger for serotonergic psychedelic effects. Studies using the close structural analog 25CN-NBOH reveal a dual action in prefrontal neurons: simultaneous excitation of synaptic input and suppression of firing rate through potassium channels.[12] This push-pull dynamic at the cellular level may explain the coexistence of heightened sensory processing with impaired executive function.
Animal EEG recordings during 25I-NBOH administration show a distinctive slow brainwave pattern (3.5–4.5 Hz) that accompanies behavioral arrest and precedes the head-twitch response.[13] Nicotine pretreatment modifies this pattern, suggesting cholinergic systems modulate the psychedelic response.[13]
Theoretical frameworks
The REBUS model (Relaxed Beliefs Under Psychedelics) provides the most relevant interpretive framework: potent 5-HT₂A agonism disrupts the brain's hierarchical processing, weakening top-down predictions and increasing neural flexibility — resulting in the perceptual shifts, enhanced meaning-attribution, and boundary dissolution characteristic of psychedelic states.citation needed The dual excitatory-inhibitory action observed with NBOH compounds[12] maps onto this framework, potentially representing the cellular substrate of relaxed cortical hierarchies. Whether 25I-NBOH promotes structural neuroplasticity — as proposed for other 5-HT₂A agonists — has not been tested directly.
- Does 25I-NBOH promote structural neuroplasticity (new synaptic connections) in cortical neurons, and does this require sustained exposure or a single dose?
- The related compound 25I-NBOMe blocks long-term potentiation in the prefrontal cortex through a mechanism not reversed by 5-HT₂A blockade[14] — does 25I-NBOH share this potentially neurotoxic property?
- Can the distinctive slow brainwave pattern observed in mice[13] be detected in human EEG, and does it correspond to identifiable subjective states?
Subjective Effects[edit]
25I-NBOH delivers a serotonergic psychedelic experience defined by its physical weight. Pronounced sympathomimetic activation — vasoconstriction, cardiovascular arousal, temperature dysregulation — forms a persistent somatic backdrop over which visual and cognitive effects unfold. At lower doses, visual enhancement and mood elevation dominate; at higher doses, intense geometric distortion, cognitive disorganization, and emotional overwhelm become prominent. Set and setting substantially shape the psychological character, and anxiety about the compound's uncertain safety profile can color the entire experience.
Within the N-benzylphenethylamine family, 25I-NBOH sits closest to 25I-NBOMe — sharing its high potency, prominent body load, and shorter duration relative to LSD. The physical activation is substantially more intense than psilocybin or DMT, and the narrower margin between common and potentially dangerous doses creates a qualitatively different risk-awareness context throughout the experience.
Effect Grid
A full psychedelic experience develops. Visual drifting becomes prominent — surfaces breathe, colors intensify dramatically, and geometric patterns overlay the visual field. Object transformations, tracers, symmetrical texture repetition, and depth perception distortion are typical. Internal hallucinations may emerge with eyes closed.
Significant body load accompanies the perceptual effects: vasoconstriction produces noticeable peripheral cooling and bodily pressures, temperature dysregulation causes alternating sensations of heat and cold, and muscle tension settles across the jaw and shoulders. Stimulation is pronounced — wakefulness is sustained and appetite is suppressed. Pupil dilation is marked.
Cognitive alteration is substantial: thought acceleration, conceptual thinking, and emotional enhancement define the mental landscape. Music enhancement is vivid. Time alteration becomes noticeable. The full duration approaches 5-8 hours, and sleep is typically difficult for several hours beyond subjective baseline return.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Geometry · Visual breathing · Tracers · Brightness alteration · Auditory enhancement · Visual morphing · Visual haze / noise · Environmental patterning · Light sensitivity · Sound sensitivity · Depth perception distortion · Perspective distortion · After-images · Symmetrical texture repetition · Auditory distortion · Visual melting · Spatial disorientation · Visual acuity enhancement · Peripheral misidentification · Visual diffraction · Peripheral vision distortion · Auditory misinterpretation · Proprioceptive distortion · Vestibular distortion · Holotropic state · Touch enhancement · Visual magnification · Synesthesia · Dreaming enhancement · Visual processing acceleration · Ganzfeld effect · Touch suppression · Flashbacks · Object transformations · Visual recursion · Internal hallucinations · External hallucinations · Visual processing suppression · Visual scenery slicing · Auditory hallucinations · Object activation · Perspective hallucinations · Visual flipping · Environmental orbism / cubism · Shadow people · Persisting hallucinations · Gustatory hallucination
Auditory enhancement · Visual morphing · Visual haze / noise · Environmental patterning · Light sensitivity · Sound sensitivity · Depth perception distortion · Perspective distortion · After-images · Symmetrical texture repetition · Auditory distortion · Visual melting · Spatial disorientation · Visual acuity enhancement · Peripheral misidentification · Visual diffraction · Peripheral vision distortion · Auditory misinterpretation · Proprioceptive distortion · Vestibular distortion · Holotropic state · Touch enhancement · Visual magnification · Synesthesia · Dreaming enhancement · Visual processing acceleration · Ganzfeld effect · Touch suppression · Flashbacks · Object transformations · Visual recursion · Internal hallucinations · External hallucinations · Visual processing suppression · Visual scenery slicing · Auditory hallucinations · Object activation · Perspective hallucinations · Visual flipping · Environmental orbism / cubism · Shadow people · Persisting hallucinations · Gustatory hallucination
Body high · Spontaneous body sensations · Heart rate perception changes · Tingling / electric sensations · Muscle tension · Appetite suppression · Dry mouth · Dizziness · Excessive sweating · Physical fatigue · Tactile euphoria · Vibrations / buzzing · Insomnia · Bodily lightness · Nausea · Dehydration sensation · Restlessness · Bruxism · Laughter fits · Motor control impairment · Bodily pressures · Body schema distortion · Headache · Involuntary body movements · Nystagmus (eye wobbles) · Trembling · Breathing alteration · Abnormal heartbeat · Increased urination · Sexual arousal enhancement · Vomiting · Seizure threshold reduction · Bodily dissociation · Tactile hallucination
Tingling / electric sensations · Muscle tension · Appetite suppression · Dry mouth · Dizziness · Excessive sweating · Physical fatigue · Tactile euphoria · Vibrations / buzzing · Insomnia · Bodily lightness · Nausea · Dehydration sensation · Restlessness · Bruxism · Laughter fits · Bodily pressures · Body schema distortion · Headache · Involuntary body movements · Nystagmus (eye wobbles) · Trembling · Breathing alteration · Abnormal heartbeat · Increased urination · Sexual arousal enhancement · Vomiting · Seizure threshold reduction · Bodily dissociation · Tactile hallucination
Introspection enhancement · Openness enhancement · Thought connectivity · Thought acceleration · Conceptual thinking · Immersion enhancement · Cognitive euphoria · Cognitive flexibility · Cognitive impairment · Multiple thought streams · Focus suppression · Creativity enhancement · Memory suppression · Humor enhancement · Cognitive fatigue · Confusion · Memory fragmentation · Thought disorganization · Increased nature relatedness · Analysis enhancement · Information processing enhancement · Synchronicity · Thought loops · Cognitive dysphoria · Delusions of sobriety · Amnesia · Delirium · Delusions
Thought acceleration · Conceptual thinking · Immersion enhancement · Cognitive euphoria · Cognitive flexibility · Cognitive impairment · Multiple thought streams · Focus suppression · Creativity enhancement · Memory suppression · Humor enhancement · Cognitive fatigue · Confusion · Memory fragmentation · Thought disorganization · Increased nature relatedness · Analysis enhancement · Information processing enhancement · Synchronicity · Thought loops · Cognitive dysphoria · Amnesia · Delirium · Delusions
Simultaneous emotions · Empathy enhancement · Anxiety · Catharsis · Dysphoria · Irritability
Dysphoria · Irritability
Disinhibition · Social connection · Sociability enhancement · Trust enhancement · Flow state · Communication enhancement · Ego inflation · Boundary dissolution · Identity alteration · Ego dissolution · Telepathic feelings
Flow state · Communication enhancement · Ego inflation · Boundary dissolution · Identity alteration · Ego dissolution · Telepathic feelings
Time cessation
Non-dual awareness · Transpersonal visions · Voidness · Death-rebirth sequence · Near-death experience · Cessation
Near-death experience · Cessation
Recursive awareness
Timeline
Sublingual absorption begins with a metallic or chemical taste. Mild alertness and first somatic signals — tingling, slight nausea, subtle body awareness changes — emerge gradually.
Rapid intensification of visual and somatic effects. Body load builds noticeably — vasoconstriction, stimulation, temperature changes. Anxiety is common during this phase as effects accelerate.
Full psychedelic effects — visual, cognitive, emotional — reach maximum intensity. Sympathomimetic activation peaks. Most intense body load.
Visual intensity gradually diminishes. Cognitive effects persist longer than perceptual changes. Body load slowly eases but stimulation continues.
Residual stimulation, possible insomnia, and lingering perceptual sensitivity. Community reports suggest 3-12 days of subtle aftereffects including mood shifts and visual sensitivity.
⚠ Avoid driving or operating machinery for at least 8 hours after administration.
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- Moderate
- Withdrawal
- None
- Tolerance buildup
- rapid
- Tolerance reset
- 14 days
- Physical
- None
- Psychological
- Negligible
- Compulsive redosing
- Negligible
- Dose escalation
- Negligible
- Cross-tol.
- LSD · psilo · mesc
Toxicity
No lethal dose, therapeutic index, or systematic toxicology data have been published for 25I-NBOH. The acute toxicity profile is inferred from the structural analog 25I-NBOMe and the broader N-benzylphenethylamine class.inferred
Acute toxicity (analog evidence)
The N-benzylphenethylamine class has been linked to 21 deaths and 51 non-fatal poisonings in Europe, all attributed to 25I-NBOMe.[4] Severe poisoning can produce muscle breakdown, blood clotting problems, metabolic acidosis, dangerously low blood sugar, kidney failure, and multi-organ failure.[15] Seizures and extreme agitation with violent behavior have been documented in multiple cases.[15][16]
Neurotoxic potential
Animal studies with 25I-NBOMe show disruption of memory-related brain processes — an impairment not reversed by blocking serotonin receptors.[14] This suggests potential cognitive harm through mechanisms beyond the primary serotonin target. Whether 25I-NBOH shares this property has not been investigated.
Misidentification and adulteration
25I-NBOH breaks down under standard forensic heat testing, causing it to be misidentified as 2C-I.[2][6] Some cases attributed to 2C-I may actually involve 25I-NBOH. Products sold as 25I-NBOH may contain entirely different substances — one documented case found a different psychedelic and a stimulant instead, causing serotonin syndrome and loss of consciousness.[3]
Psychological risks
Acute psychological distress — panic and overwhelming fear — is documented in clinical cases involving related N-benzylphenethylamine compounds.[17] Agitation, confusion, and excited delirium occur at high doses.[15] Community reports describe perceptual or cognitive disturbances lasting 3–12 days after use.
Hallucinogen persisting perception disorder (hallucinogen-persisting perception disorder) is documented for serotonergic psychedelics as a class but has not been specifically reported for 25I-NBOH.citation needed People with personal or family histories of psychotic disorders or bipolar disorder face elevated risk of psychiatric destabilization.
Tolerance and dependence
25I-NBOH is not habit-forming. Tolerance builds rapidly after a single dose — the brain downregulates its serotonin receptors — with full reset estimated at approximately two weeks.inferred This rapid tolerance inherently limits compulsive use.
Cross-tolerance with LSD, psilocybin, mescaline, and other NBOH/NBOMe compounds is expected given the shared receptor mechanism. No physical dependence or withdrawal has been described for any NBOH compound.
Drug Interactions
The primary risk is serotonin syndrome — dangerous overheating, muscle rigidity, and rapid heart rate. Combining 25I-NBOH with any drug that raises serotonin levels can trigger this: MAOIs, SSRIs, and SNRIs interact this way.safety citation needed Tramadol is classified as a dangerous interaction — it raises serotonin[18] and independently lowers the seizure threshold.[15]
A separate risk involves the liver enzyme CYP2D6, which the body uses to clear 25I-NBOH.[9] Drugs that block this enzyme — including fluoxetine, paroxetine, and bupropion — can substantially increase drug levels. Fluoxetine and paroxetine carry double risk: they block CYP2D6 and raise serotonin simultaneously.
Contraindications
5 knownSevere heart conditions are an absolute contraindication. The N-benzylphenethylamine class raises heart rate, blood pressure, and constricts blood vessels[15] — dangerous with coronary artery disease, uncontrolled high blood pressure, or recent stroke. Seizure disorders are also an absolute contraindication, as seizures are a documented complication of severe poisoning from this class.[16][15]
Concurrent serotonergic medications — MAOIs, SSRIs, SNRIs, tramadol — are contraindicated due to serotonin syndrome risk. CYP2D6 poor metabolizer status is a relative contraindication, as non-functional CYP2D6 genes may substantially elevate and prolong effects.[9] Personal or family history of psychotic or bipolar disorder is also a relative contraindication.citation needed
Harm Reduction[edit]
Forms & Identification
Blotter paper containing 25I-NBOH is visually indistinguishable from LSD, 25I-NBOMe, or dozens of other compounds. Standard forensic gas chromatography misidentifies it as 2C-I because the compound breaks down under heat.[2] The same limitation applies to some field test interpretations.
Reagent testing can narrow identification but cannot confirm 25I-NBOH specifically. A bitter, numbing taste on the tongue indicates an N-benzylphenethylamine compound and distinguishes it from LSD, which is tasteless. Liquid chromatography is the only reliable confirmation method.
Guidelines
- Test all material with reagent kits before use. A bitter or numbing taste indicates an N-benzylphenethylamine compound, not LSD.
- Start with the lowest reported threshold dose and wait at least 90 minutes before considering effects fully developed. Sublingual absorption is variable.
- Stay in a comfortable, temperature-controlled environment. Keep water accessible.
- Have a sober, trusted companion present throughout the experience.
- Avoid physical exertion — cardiovascular strain is already elevated.
- If the experience becomes distressing, move to a quiet space and focus on slow, steady breathing. Effects typically resolve within 5–8 hours.
Set & Setting
The pronounced physical intensity of 25I-NBOH makes environment especially important. A calm, temperature-controlled setting helps manage vasoconstriction and temperature changes characteristic of the experience. A trusted, sober companion is strongly recommended given the compound's poorly characterized dose-response curve.
Anxiety about the compound's safety profile can itself shape the experience. Entering with unresolved apprehension increases the likelihood of a difficult psychological response.
Aftercare & integration. Perceptual or cognitive disturbances can linger for 3–12 days after use. Physical recovery may include fatigue, muscle soreness from sustained vasoconstriction, and appetite disruption.
Allow at least two weeks before any subsequent psychedelic use — this covers the tolerance reset window and allows full physical and psychological recovery. If perceptual disturbances persist beyond two weeks, consult a healthcare professional — persistent visual changes after psychedelic use may indicate HPPD.
Recovery & Support
25I-NBOH is not considered habit-forming, and compulsive use is self-limiting due to rapid tolerance. If psychedelic use is causing distress, impairing daily functioning, or being used to avoid underlying problems, professional support can help.
The Fireside Project (62-FIRESIDE / 623-473-7433) offers peer support for psychedelic experiences. SAMHSA's National Helpline (1-800-662-4357) provides free, confidential treatment referrals.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency
Uncomfortable effects — nausea, anxiety, vasoconstriction — are distinct from medical emergencies. Seek immediate help if any of the following occur:
- Seizures or uncontrollable muscle rigidity
- Chest pain or irregular heartbeat
- Body temperature hot to the touch through clothing
- Loss of consciousness or inability to respond
- Extreme agitation with violent behavior or self-harm risk
- Confusion so severe the person cannot recognize their surroundings
Immediate steps
- 1. Call emergency services immediately.
- 2. Place the person on their side (recovery position) if unconscious but breathing.
- 3. Do not restrain unless there is immediate danger to the person or others.
- 4. Remove excess clothing and cool the skin if body temperature is elevated.
- 5. Stay with the person and keep them calm until help arrives.
- 6. Do not induce vomiting.
What to tell the dispatcher
State the substance name (25I-NBOH or "an NBOMe-type compound"), approximate amount if known, time of ingestion, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug-related emergency.
Legal Status[edit]
As of 2017, 25I-NBOH was not controlled under United Nations international drug conventions.[2] National scheduling has followed on a jurisdiction-by-jurisdiction basis, generally trailing behind the more documented 25I-NBOMe.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States (federal) | Not explicitly DEA-scheduled | May be prosecuted under the Federal Analogue Act (21 U.S.C. § 813) if intended for human consumption[7] |
| United States (Louisiana) | Schedule I | Scheduled June 2013[7] |
| United Kingdom | Effectively banned | Covered under the Psychoactive Substances Act 2016citation needed |
| Sweden | Controlled substance | Added under the Narcotic Drugs Punishments Act, effective August 18, 2015[7] |
| Brazil | Controlled substance | Added to the national controlled substances list[2] |
| Canada | Not explicitly scheduled | Potential coverage under analog provisions of the Controlled Drugs and Substances Actcitation needed |
| Australia | Likely controlled | Probable coverage under analog provisionscitation needed |
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- Moderate
- Withdrawal
- None
- Tolerance buildup
- rapid
- Tolerance reset
- 14 days
- Physical
- None
- Psychological
- Negligible
- Compulsive redosing
- Negligible
- Dose escalation
- Negligible
- Cross-tol.
- LSD · psilo · mesc
Toxicity
No lethal dose, therapeutic index, or systematic toxicology data have been published for 25I-NBOH in any species. The acute toxicity profile is inferred from the structural analog 25I-NBOMe and the broader N-benzylphenethylamine class.inferred
Acute toxicity (analog evidence)
The N-benzylphenethylamine class has been linked to 21 deaths and 51 non-fatal poisonings in Europe, attributed to 25I-NBOMe.[5] Severe poisoning from this class can produce muscle breakdown, blood clotting dysfunction, metabolic acidosis, dangerously low blood sugar, kidney failure, and multi-organ failure.[15] Seizures and extreme agitation with violent behavior have been documented in multiple cases.[15][16]
Neurotoxic potential
Animal studies with 25I-NBOMe show disruption of sensory gating, increased dopamine release, and blockade of long-term potentiation in the prefrontal cortex — with the memory-related impairment not reversed by blocking 5-HT₂A receptors.[14] This suggests cognitive harm through mechanisms beyond the primary serotonin target. Whether 25I-NBOH shares this property has not been investigated.
Misidentification and adulteration
25I-NBOH's thermal instability causes it to be misidentified as 2C-I in forensic laboratories using standard gas chromatography.[3][7] This means some cases attributed to 2C-I may actually involve 25I-NBOH. Conversely, products sold as 25I-NBOH may contain other substances entirely — one documented case found 25E-NBOH and the stimulant MDPHP instead, which caused serotonin syndrome and loss of consciousness.[4]
Psychological risks
No controlled studies document the psychological risk profile of 25I-NBOH specifically. Acute psychological distress including panic and overwhelming fear is documented in clinical presentations involving related N-benzylphenethylamine compounds.[17] Agitation, confusion, and excited delirium occur at high doses.[15]
Hallucinogen persisting perception disorder (hallucinogen-persisting perception disorder) is documented for serotonergic psychedelics as a class but has not been specifically reported for 25I-NBOH.citation needed Community reports describe lingering perceptual or cognitive disturbances lasting 3–12 days. Individuals with personal or family histories of psychotic disorders or bipolar disorder face elevated risk of psychiatric destabilization.
Tolerance and dependence
25I-NBOH is not habit-forming. Like all serotonergic psychedelics, it produces rapid tolerance through downregulation — tolerance builds quickly after a single dose, with full reset estimated at approximately two weeks.inferred This rapid tolerance inherently limits compulsive use.
Cross-tolerance with other serotonergic psychedelics — including LSD, psilocybin, mescaline, and other NBOH/NBOMe compounds — is expected given the shared receptor mechanism. No physical dependence or withdrawal has been described for 25I-NBOH or any member of the NBOH series.
Drug Interactions
The primary risk involves serotonergic potentiation. 25I-NBOH is a potent 5-HT₂A/₂C agonist; combining it with any agent that raises serotonin levels creates risk of serotonin syndrome — a potentially life-threatening condition involving dangerously high body temperature, muscle rigidity, rapid heart rate, and agitation.
Tramadol carries dual risk: it blocks serotonin reuptake, potentiating serotonergic toxicity,[18] and independently lowers the seizure threshold[15] — compounding the seizure risk associated with high-dose N-benzylphenethylamine use. This interaction is classified as dangerous.
MAOIs, SSRIs, and SNRIs interact through analogous serotonergic mechanisms. MAOIs pose the highest risk by preventing serotonin breakdown; SSRIs and SNRIs block serotonin reuptake.safety citation needed
A separate pharmacokinetic interaction operates through CYP2D6 inhibition. Because 25I-NBOH depends on CYP2D6 for metabolism,[10] co-administration with strong CYP2D6 inhibitors (fluoxetine, paroxetine, bupropion, quinidine) may substantially increase drug levels. Fluoxetine and paroxetine carry compounded risk: they inhibit both CYP2D6 (slowing clearance) and serotonin reuptake (increasing serotonin load).
Cannabis interaction severity is uncharacterized. No direct pharmacological mechanism linking cannabinoid and 5-HT₂A-mediated psychedelia has been established, though community reports describe intensified or destabilized effects.
Contraindications
5 knownContraindication data are derived entirely from class pharmacology; no substance-specific studies exist.inferred
Severe heart conditions constitute an absolute contraindication. The N-benzylphenethylamine class produces rapid heart rate, elevated blood pressure, and vasoconstriction[15] — dangerous in the setting of coronary artery disease, uncontrolled high blood pressure, or recent stroke.
Seizure disorders are an absolute contraindication. Seizures are a documented complication of severe N-benzylphenethylamine poisoning.[16][15]
Concurrent serotonergic medications — including MAOIs, SSRIs, SNRIs, and tramadol — are contraindicated due to serotonin syndrome risk.
CYP2D6 poor metabolizer status is a relative contraindication. Individuals with non-functional CYP2D6 genes may experience substantially elevated and prolonged effects.[10]
Psychotic disorders and bipolar disorder (personal or family history) are relative contraindications.citation needed
Harm Reduction[edit]
Forms & Identification
25I-NBOH on blotter paper is visually indistinguishable from LSD, 25I-NBOMe, or dozens of other active compounds sold on blotter. The compound's thermal instability means standard forensic gas chromatography misidentifies it as 2C-I[3] — the same limitation applies to some field testing interpretations.
Reagent testing can help narrow the identification but cannot confirm 25I-NBOH specifically. A bitter, numbing taste on the tongue is characteristic of N-benzylphenethylamine compounds and distinguishes them from LSD (which is tasteless); however, taste alone cannot differentiate between NBOH and NBOMe variants. Verified analytical testing (liquid chromatography) is the only reliable confirmation method.
Guidelines
- Test all material with reagent kits before use. A bitter or numbing taste indicates an N-benzylphenethylamine compound, not LSD.
- Start with the lowest reported threshold dose and wait at least 90 minutes before considering the effects have fully developed. Sublingual absorption is variable.
- Remain in a comfortable, temperature-controlled environment. Keep water accessible.
- Have a sober, trusted companion present throughout the experience.
- Avoid physical exertion — cardiovascular strain is already elevated.
- If the experience becomes distressing, move to a quiet space and focus on slow, steady breathing. Effects typically resolve within 5–8 hours.
Set & Setting
The pronounced physical intensity and cardiovascular activation of 25I-NBOH make environment particularly important. A calm, temperature-controlled setting helps manage the vasoconstriction and body temperature dysregulation characteristic of the experience. A trusted, sober companion is strongly recommended given the compound's poorly characterized dose-response curve and the documented potential for confused or agitated states at higher doses.
Anxiety about the compound's safety profile — its uncharacterized margin of safety, its association with the NBOMe class — can itself substantially shape the experience. Entering the experience in a state of unresolved apprehension increases the likelihood of difficult psychological responses.
Aftercare & integration. Community reports describe lingering perceptual or cognitive disturbances lasting 3–12 days following 25I-NBOH use. Physical recovery may include fatigue, muscle soreness from sustained vasoconstriction, and appetite disruption.
Allow at least two weeks before any subsequent psychedelic use — this reflects the estimated tolerance reset window and allows for full physical and psychological recovery. Journaling or discussing the experience with a trusted person can help process intense or confusing content. If perceptual disturbances persist beyond two weeks, consult a healthcare professional — persistent visual changes after psychedelic use may indicate HPPD.
Recovery & Support
25I-NBOH is not considered habit-forming, and compulsive use is self-limiting due to rapid tolerance. However, patterns of escalating novel psychoactive substance use may indicate broader issues with substance use or risk-seeking behavior.
If psychedelic use is causing distress, impairing daily functioning, or being used to avoid addressing underlying problems, professional support can help. The Fireside Project (62-FIRESIDE / 623-473-7433) offers peer support for psychedelic experiences. SAMHSA's National Helpline (1-800-662-4357) provides free, confidential treatment referrals.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency
Uncomfortable effects (nausea, anxiety, vasoconstriction) are distinct from medical emergencies. Seek immediate help if any of the following occur:
- Seizures or uncontrollable muscle rigidity
- Chest pain or irregular heartbeat
- Body temperature hot to the touch through clothing
- Loss of consciousness or inability to respond
- Extreme agitation with violent behavior or self-harm risk
- Confusion so severe the person cannot recognize their surroundings
Immediate steps
- 1. Call emergency services immediately.
- 2. Place the person on their side (recovery position) if unconscious but breathing.
- 3. Do not restrain unless there is immediate danger to the person or others.
- 4. Remove excess clothing and cool the skin if body temperature is elevated.
- 5. Stay with the person and keep them calm until help arrives.
- 6. Do not induce vomiting.
What to tell the dispatcher
State the substance name (25I-NBOH or "an NBOMe-type compound"), approximate amount if known, time of ingestion, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug-related emergency.
Legal Status[edit]
As of 2017, 25I-NBOH was not subject to control under United Nations international drug conventions.[3] National scheduling has proceeded on a jurisdiction-by-jurisdiction basis, generally lagging behind the more documented 25I-NBOMe. The compound's legal status in most countries remains either unscheduled or covered indirectly through structural analog or blanket novel psychoactive substance legislation.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States (federal) | Not explicitly DEA-scheduled | May be prosecuted under the Federal Analogue Act (21 U.S.C. § 813) if intended for human consumption[8] |
| United States (Louisiana) | Schedule I | Scheduled June 2013[8] |
| United Kingdom | Effectively banned | Covered under the Psychoactive Substances Act 2016citation needed |
| Sweden | Controlled substance | Added under the Narcotic Drugs Punishments Act, effective August 18, 2015[8] |
| Brazil | Controlled substance | Added to the national controlled substances list[3] |
| Canada | Not explicitly scheduled | Potential coverage under analog provisions of the Controlled Drugs and Substances Actcitation needed |
| Australia | Likely controlled | Probable coverage under analog provisionscitation needed |
Frequently asked questions
What is 25I-NBOH?
25I-NBOH is a synthetic psychedelic phenethylamine of the NBOH series, active at microgram doses via sublingual administration. It acts as a full agonist at serotonin 5-HT2A and 5-HT2C receptors with subnanomolar functional potency, primarily metabolized by CYP2D6.
How long does 25I-NBOH last?
Total duration by route of administration — Sublingual: 5 – 8 hours. Ranges vary with dose and individual factors; see the duration table for onset, peak, and after-effect phases.
Where can I find dosage information for 25I-NBOH?
Psychedex publishes a dosage table for 25I-NBOH on this page covering these routes of administration: sublingual. Dose values are presented only in that table, always alongside their route of administration.
What are dangerous combinations with 25I-NBOH?
The highest-severity documented interactions for 25I-NBOH: MAOIs (Lethal), Buspirone (Dangerous), Dopamine agonists (Dangerous), GHB, Baclofen (Dangerous), GHB, GBL (Dangerous). See the interactions section for the full list with mechanisms and severity levels.
Is 25I-NBOH addictive?
Psychedex records tolerance and dependence data rather than a yes/no rating. Recorded tolerance indicators for 25I-NBOH: tolerance builds rapid; full reset takes 14 days; cross-tolerance develops with LSD, psilocybin, mescaline, 25I-NBOMe, 25CN-NBOH, other NBOH compounds, other serotonergic psychedelics. See the article's dependence and safety sections for recorded dependence data.
experience reports
No experience reports yet. Be the first to contribute.
First-person accounts of subjective effects, timing, and outcomes — submitted for harm reduction.
references
- [1] ^abcBraden MR, Parrish JC, Naylor JC, Nichols DE (2006) Molecular interaction of serotonin 5-HT2A receptor residues Phe339(6.51) and Phe340(6.52) with superpotent N-benzyl phenethylamine agonists — Molecular Pharmacology PMID:17000863
- [2]
- [3] ^abcPelletier R, Gicquel T, Carvelli J, Balaz P, Pelissier-Alicot AL, Morel I, Bottinelli C, Solas C, Le Dare B, Fabresse N (2024) Severe 25E-NBOH intoxication associated with MDPHP intake: a case report, metabolism study, and literature review — International Journal of Legal Medicine doi:10.1007/s00414-023-03151-6
- [4] ^abKaminska K, Swit P, Malek K (2021) 2-(4-Iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (25I-NBOME): A Harmful Hallucinogen Review — Journal of Analytical Toxicology doi:10.1093/jat/bkaa022
- [5] ^Chia XWS, Ong MC, Yeo YYC, Ho YJ, Binte Ahmad Nasir EI, Tan LJ, Chua PY, Yap TWA, Lim JLW (2019) Simultaneous analysis of 2Cs, 25-NBOHs, 25-NBOMes and LSD in seized exhibits using liquid chromatography-tandem mass spectrometry: A targeted approach — Forensic Science International doi:10.1016/j.forsciint.2019.05.036
- [6] ^abKupriyanova OV, Shevyrin VA, Sadykova RG, Shafran YM (2024) Identification of thermolabile positional isomers of N-(2-hydroxybenzyl)-2-(dimethoxyphenyl)ethanamines (NBOH series) using chromatography and mass spectrometry methods — Drug Testing and Analysis doi:10.1002/dta.3648
references
- [1] ^abWallach J, Cao AB, Calkins MM, Heim AJ, Lanham JK, et al. (2023) Identification of 5-HT2A receptor signaling pathways associated with psychedelic potential — Nature Communications doi:10.1038/s41467-023-44016-1
- [2] ^abcBraden MR, Parrish JC, Naylor JC, Nichols DE (2006) Molecular interaction of serotonin 5-HT2A receptor residues Phe339(6.51) and Phe340(6.52) with superpotent N-benzyl phenethylamine agonists — Molecular Pharmacology PMID:17000863
- [3]
- [4] ^abcPelletier R, Gicquel T, Carvelli J, Balaz P, Pelissier-Alicot AL, Morel I, Bottinelli C, Solas C, Le Dare B, Fabresse N (2024) Severe 25E-NBOH intoxication associated with MDPHP intake: a case report, metabolism study, and literature review — International Journal of Legal Medicine doi:10.1007/s00414-023-03151-6
- [5] ^abKaminska K, Swit P, Malek K (2021) 2-(4-Iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (25I-NBOME): A Harmful Hallucinogen Review — Journal of Analytical Toxicology doi:10.1093/jat/bkaa022
- [6] ^abcChia XWS, Ong MC, Yeo YYC, Ho YJ, Binte Ahmad Nasir EI, Tan LJ, Chua PY, Yap TWA, Lim JLW (2019) Simultaneous analysis of 2Cs, 25-NBOHs, 25-NBOMes and LSD in seized exhibits using liquid chromatography-tandem mass spectrometry: A targeted approach — Forensic Science International doi:10.1016/j.forsciint.2019.05.036